957 related articles for article (PubMed ID: 37306737)
41. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
42. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
Long J; Qu T; Pan XF; Tang X; Wan HH; Qiu P; Xu YH
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1188-S1192. PubMed ID: 30539869
[TBL] [Abstract][Full Text] [Related]
43. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
[TBL] [Abstract][Full Text] [Related]
44. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
45. MiR-155 regulates M2 polarization of hepatitis B virus-infected tumour-associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma.
Fei Y; Wang Z; Huang M; Wu X; Hu F; Zhu J; Yu Y; Shen H; Wu Y; Xie G; Zhou Z
J Viral Hepat; 2023 May; 30(5):417-426. PubMed ID: 36704832
[TBL] [Abstract][Full Text] [Related]
46. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
47. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
48. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.
Wang BJ; Bao JJ; Wang JZ; Wang Y; Jiang M; Xing MY; Zhang WG; Qi JY; Roggendorf M; Lu MJ; Yang DL
World J Gastroenterol; 2011 Jul; 17(28):3322-9. PubMed ID: 21876620
[TBL] [Abstract][Full Text] [Related]
49. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.
Wu R; Liu W; Yang Q; Zhang J; Hou P; Xiong J; Wu L; Li E
Sci Rep; 2023 Oct; 13(1):16998. PubMed ID: 37813900
[TBL] [Abstract][Full Text] [Related]
50. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
51. Role of NCF2 as a potential prognostic factor and immune infiltration indicator in hepatocellular carcinoma.
Huang N; Zhang J; Kuang S; Li Z; Zhao H; Wu J; Liu M; Wang L
Cancer Med; 2023 Apr; 12(7):8991-9004. PubMed ID: 36680322
[TBL] [Abstract][Full Text] [Related]
52. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
[TBL] [Abstract][Full Text] [Related]
53. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
54. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence.
Cui L; Tian X; Yan L; Guan X; Dong B; Zhao M; Lv A; Liu D; Wu J; Hao C
Int J Med Sci; 2022; 19(13):1977-1988. PubMed ID: 36438917
[No Abstract] [Full Text] [Related]
55. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
56. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X; Zhang H; Zhou Z; Chen M; Wang Q
Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
[TBL] [Abstract][Full Text] [Related]
57. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Iseda N; Itoh S; Yoshizumi T; Yugawa K; Morinaga A; Tomiyama T; Toshima T; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Apr; 5(4):675-688. PubMed ID: 33860125
[TBL] [Abstract][Full Text] [Related]
58. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
59. CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma.
Su Q; Li L; Li X; Li W; Zhang X; Dong Y; Han L; Wang D; Ran J
World J Surg Oncol; 2022 Dec; 20(1):382. PubMed ID: 36464675
[TBL] [Abstract][Full Text] [Related]
60. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Liu J; Li H; Sun L; Yuan Y; Xing C
Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]